Showing results (691-700 of 782) with videos related to

Sort By:
Pageof 79
Blood|August 11, 2007
Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trialPaul G Richardson, Pieter Sonneveld, Michael Schuster, et al.
The New England Journal of Medicine|August 30, 2008
Bortezomib plus melphalan and prednisone for initial treatment of multiple myelomaJesús F San Miguel, Rudolf Schlag, Nuriet K Khuageva, et al.
Blood Cancer Journal|February 15, 2020
Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myelomaMeletios A Dimopoulos, Andrzej J Jakubowiak, Philip L McCarthy, et al.
Blood|October 18, 2012
Prediagnosis biomarkers of insulin-like growth factor-1, insulin, and interleukin-6 dysregulation and multiple myeloma risk in the Multiple Myeloma Cohort ConsortiumBrenda M Birmann, Marian L Neuhouser, Bernard Rosner, et al.
The New England Journal of Medicine|June 17, 2005
Bortezomib or high-dose dexamethasone for relapsed multiple myelomaPaul G Richardson, Pieter Sonneveld, Michael W Schuster, et al.
The Journal of Clinical Investigation|January 26, 2008
Pharmacologic targeting of a stem/progenitor population in vivo is associated with enhanced bone regeneration in miceSiddhartha Mukherjee, Noopur Raje, Jesse A Schoonmaker, et al.
Blood|January 19, 2017
Functional role and therapeutic targeting of p21-activated kinase 4 in multiple myelomaMariateresa Fulciniti, Joaquin Martinez-Lopez, William Senapedis, et al.
Blood Cancer Journal|July 8, 2026
WNK2 oncogenicity revealed by the discovery and functional characterization of novel gene isoforms in MYD88 mutated Waldenström's MacroglobulinemiaMaria Luisa Guerrera, Xia Liu, Nickolas Tsakmaklis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 14, 2021
Single-Cell Profiling Reveals Metabolic Reprogramming as a Resistance Mechanism in BRAF-Mutated Multiple MyelomaJohannes M Waldschmidt, Jake A Kloeber, Praveen Anand, et al.
British Journal of Haematology|May 10, 2018
A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myelomaElizabeth K O'Donnell, Jacob P Laubach, Andrew J Yee, et al.
Pageof 79